이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Medtronic 관리

관리 기준 확인 3/4

Medtronic's CEO는 Geoff Martha, Apr2020 에 임명되었습니다 의 임기는 4.17 년입니다. 총 연간 보상은 $ 15.39M, 8.8% 로 구성됩니다. 8.8% 급여 및 91.2% 보너스(회사 주식 및 옵션 포함). 는 € 10.64M 가치에 해당하는 회사 주식의 0.011% 직접 소유합니다. 10.64M. 경영진과 이사회의 평균 재임 기간은 각각 3.4 년과 9.4 년입니다.

주요 정보

Geoff Martha

최고 경영자

US$15.4m

총 보상

CEO 급여 비율	8.8%
CEO 임기	4.2yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	3.4yrs
이사회 평균 재임 기간	9.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Geoff Martha 의 보수는 Medtronic 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Apr 26 2024	n/a	n/a	US$4b
Jan 26 2024	n/a	n/a	US$4b
Oct 27 2023	n/a	n/a	US$4b
Jul 28 2023	n/a	n/a	US$4b
Apr 28 2023	US$15m	US$1m	US$4b
Jan 27 2023	n/a	n/a	US$4b
Oct 28 2022	n/a	n/a	US$4b
Jul 29 2022	n/a	n/a	US$5b
Apr 29 2022	n/a	n/a	US$5b
Jan 28 2022	n/a	n/a	US$5b
Oct 29 2021	n/a	n/a	US$5b
Jul 30 2021	n/a	n/a	US$4b
Apr 30 2021	US$18m	US$1m	US$4b
Jan 29 2021	n/a	n/a	US$3b
Oct 30 2020	n/a	n/a	US$4b
Jul 31 2020	n/a	n/a	US$4b
Apr 24 2020	US$6m	US$905k	US$5b
Jan 24 2020	n/a	n/a	US$5b
Oct 25 2019	n/a	n/a	US$5b
Jul 26 2019	n/a	n/a	US$4b
Apr 26 2019	US$4m	US$693k	US$5b

보상 대 시장: Geoff 의 총 보상 ($USD 15.39M )은 BG 시장( $USD 4.48M ).

보상과 수익: Geoff 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Geoff Martha (54 yo)

4.2yrs

테뉴어

US$15,394,632

보상

Mr. Geoffrey Straub Martha, also known as Geoff, serves as Director at Medtronic plc since November 01, 2019 and serves as its Chief Executive Officer since April 27, 2020. He serves as Chairman at Medtron...

리더십 팀

이름	위치	테뉴어	보상	소유권
Geoffrey Martha	Chairman of the Board & CEO	4.2yrs	US$15.39m	0.011% $ 10.5m
Karen Parkhill	Executive VP & CFO	8yrs	US$6.12m	0.0052% $ 4.9m
Sean Salmon	Executive VP & President of Cardiovascular Portfolio	no data	US$5.36m	0.0019% $ 1.8m
Robert J. ten Hoedt	Executive VP & President of Global Regions	9.4yrs	US$5.05m	0.0024% $ 2.3m
Mark Ploof	Senior Vice President of Global Operations and Business Services	7.7yrs	데이터 없음	데이터 없음
Jennifer Kirk	Senior VP	3yrs	데이터 없음	0.0010% $ 970.4k
Kenneth Washington	Senior VP and Chief Technology & Innovation Officer	less than a year	데이터 없음	데이터 없음
Laura Mauri	Senior VP and Chief Scientific & Medical Officer	2.2yrs	데이터 없음	데이터 없음
Ryan Weispfenning	VP & Head of Investor Relations	9yrs	데이터 없음	데이터 없음
Ivan Fong	Executive VP	2.3yrs	US$11.72m	0.00085% $ 800.8k
Torod Neptune	Senior VP & Chief Communications Officer	3.4yrs	데이터 없음	데이터 없음
Matt Walter	Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: 2M6 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Geoffrey Martha	Chairman of the Board & CEO	4.6yrs	US$15.39m	0.011% $ 10.5m
Scott Donnelly	Independent Director	11.4yrs	US$365.01k	0.0014% $ 1.3m
Kendall Powell	Independent Director	17.4yrs	US$350.01k	0.0034% $ 3.2m
Randall Hogan	Independent Director	9.4yrs	US$385.01k	0.0034% $ 3.2m
Craig Arnold	Lead Independent Director	9.4yrs	US$410.01k	0.0028% $ 2.7m
Denise O'Leary	Independent Director	24.4yrs	US$375.01k	0.0060% $ 5.7m
Andrea Goldsmith	Independent Director	5.3yrs	US$370.01k	0.00048% $ 452.2k
Elizabeth Nabel	Independent Director	10.4yrs	US$370.01k	0.0010% $ 989.3k
Lidia Fonseca	Independent Director	2yrs	US$294.37k	0.00012% $ 113.1k
Kevin Lofton	Independent Director	3.8yrs	US$370.01k	0.00032% $ 301.5k
Gregory Lewis	Independent Director	less than a year	데이터 없음	데이터 없음

9.4yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 2M6 의 이사회는 경험(평균 재직 기간 9.4 년)으로 간주됩니다.

Medtronic 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Recent updates

New minor risk - Earnings quality

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Full year 2024 earnings released: EPS: US$2.77 (vs US$2.83 in FY 2023)

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

New minor risk - Earnings quality

Full year 2024 earnings released: EPS: US$2.77 (vs US$2.83 in FY 2023)

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Now 20% undervalued after recent price drop

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Third quarter 2024 earnings released: EPS: US$0.99 (vs US$0.92 in 3Q 2023)

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Second quarter 2024 earnings released: EPS: US$0.68 (vs US$0.32 in 2Q 2023)

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Now 21% undervalued after recent price drop

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Now 20% undervalued after recent price drop

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: US$0.59 (vs US$0.70 in 1Q 2023)

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Full year 2023 earnings released: EPS: US$2.83 (vs US$3.75 in FY 2022)

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Third quarter 2023 earnings released: EPS: US$0.92 (vs US$1.10 in 3Q 2022)

Medtronic plc to Report Q3, 2024 Results on Feb 20, 2024

Medtronic Linq Insertable Cardiac Monitor Detects 10 Times More Atrial Fibrillation in Ischemic Stroke Patients At Three Years Compared to Standard of Care

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Medtronic Announces First Patient Enrolled in U.S. Clinical Trial for Hugo™ Robotic-Assisted Surgery System

Medtronic plc Approves Cash Dividend for the Third Quarter of Fiscal Year 2023, Payable on January 13, 2023

Medtronic Completes Enrollment in Pivotal Trial Evaluating First-Of-Its-Kind Pulsed Field Ablation Catheter for Patients with Atrial Fibrillation

Second quarter 2023 earnings released: EPS: US$0.32 (vs US$0.97 in 2Q 2022)

Medtronic plc Provides Revenue Results for the Second Half of 2023

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령